Physician profile
Abby M Levitz
NPI 1083918833
$2,063.55
in general payments reported to CMS, 2019-2025
20 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $252 · 2023: $439 · 2024: $643 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $603.43 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $190.62 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $168.88 | 2022-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $137.66 | 2022-2025 | Gvoke Hypopen |
| Abbvie INC. | $137.56 | 2024-2025 | |
| Pfizer INC. | $130.82 | 2024-2025 | |
| Adlon Therapeutics L.P. | $115.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.72 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $82.76 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $79.20 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.87 | 2025 | Caplyta |
| Amgen INC. | $58.90 | 2022-2024 | Repatha, Otezla, Prolia |
| Abbott Laboratories | $47.01 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $41.19 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $28.30 | 2024-2025 | Shingrix, Arexvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $17.00 | 2025 | Jornay Pm |
| Bayer Healthcare Pharmaceuticals INC. | $14.83 | 2025 | |
| Esperion Therapeutics, INC. | $13.73 | 2023 | Nexletol |
| Ironshore Pharmaceuticals INC. | $13.38 | 2024 | |
| Bausch Health US, LLC | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Levitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.